Ultomiris and ZEGFROVY approvals lift AstraZeneca stock as buyer support prevails

Traders Union
All News
Stocks
AstraZeneca jumps 2.49% after FDA news

Highlights

AstraZeneca received accelerated FDA approval for Ultomiris in primary immunoglobulin A nephropathy, giving immediate U.S. market access for this rare kidney disorder therapy.
Further growth drivers include ZEGFROVY's accelerated approval for lung cancer, strong full-year results, and positive late-stage TEZSPIRE trial data.
Shares of AstraZeneca surged 2.49% to GBX12,928 with strong bullish technical signals; next sessions are expected to trade in the GBX12,623 to GBX13,233 range.

U.S. approvals and new launches expand revenue and drive optimism

AstraZeneca has secured accelerated approval from the U.S. FDA for Ultomiris (ravulizumab) to treat primary immunoglobulin A nephropathy (IgAN), a rare kidney disorder, creating immediate access to the U.S. market for this therapy and expanding the company's revenue base, according to Yahoo Finance. The U.S. launch of ZEGFROVY (Sunvozertinib) following its accelerated FDA approval adds further growth potential in the lung cancer segment. In addition, AstraZeneca recently disclosed robust full-year financials and reported positive Phase III results for TEZSPIRE in eosinophilic esophagitis, as well as a new AI-focused collaboration with Abu Dhabi Biobank, signaling strength in both core and innovative franchises.

Bullish signals persist as overbought readings heighten exhaustion risk

On the technical front, AZN is trading above its MA-20 at GBX12,660 and MA-50 at GBX12,548, but remains below its long-term MA-200 at GBX13,462. The Ichimoku Kijun at GBX12,691 marks immediate support. Indicators are decisively bullish—MACD and ADX favor buyers, while RSI, Stoch RSI, CCI, and Bull/Bear Power all register in overbought territory, reflecting strong buyer momentum but also a risk of near-term exhaustion. The Awesome Oscillator supports the present upward trend, and intraday price action confirms persistent volatility and bullish pressure.

Price consolidation expected amid volatility and breakout triggers

Over the next several sessions, AZN is expected to fluctuate within a GBX12,623 to GBX13,233 range. The probability of further price gains stands at 76%, with a 24% likelihood of a short-term pullback. A breakout above GBX13,233 would open the door to additional upside, while a drop below immediate support at GBX12,691 could trigger a retracement. The baseline expectation is for price consolidation in the established volatility band.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca’s move as technically strong but not yet secure for new buyers. He notes that recent FDA approvals and robust financials create positive sentiment and expand the addressable market. However, the stock remains below its long-term MA-200 and is overbought on several indicators, signaling possible exhaustion. "The base scenario is consolidation in the current range — I would stay defensive until GBX13,233 is clearly broken on strong volume."

Earlier, analysts noted that AstraZeneca was likely to remain in a consolidation phase, supported by advances in its clinical pipeline and AI-driven research initiatives. With multiple FDA approvals and clear signs of upward momentum, traders should watch for a decisive breakout above GBX13,233 to validate the next stage of trend continuation.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.